009300 — Sam-A Pharm Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩199bn
- KR₩130bn
- KR₩97bn
- 94
- 75
- 56
- 91
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 71,560 | 53,653 | 54,666 | 81,700 | 97,211 |
Cost of Revenue | |||||
Gross Profit | 43,685 | 32,370 | 32,658 | 50,163 | 61,624 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 61,163 | 49,722 | 48,618 | 63,446 | 73,711 |
Operating Profit | 10,397 | 3,930 | 6,048 | 18,253 | 23,500 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 13,051 | 1,573 | 5,335 | 18,400 | 28,476 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10,197 | 124 | 3,392 | 11,912 | 21,374 |
Net Income Before Extraordinary Items | |||||
Net Income | 10,197 | 124 | 3,392 | 11,912 | 21,374 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10,197 | 124 | 3,392 | 11,912 | 21,374 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1,671 | 1.01 | 521 | 1,953 | 3,481 |
Dividends per Share |